In a neuroblastoma xenograft model, anti-GD2 CAR T cells co-administered with the anti-VEGF antibody bevacizumab had superior anti-tumor activity over GD2 CAR T cells alone, thought to be primarily related to increased tumor infiltration by T cells (140). Here, VEGFA is linked to neoplasm.